medigraphic.com
ISSN 1560-4381 (Impreso)

2020, Número 4

<< Anterior Siguiente >>

Correo Científico Médico 2020; 24 (4)


Manejo del síndrome antifosfolipídico primario en el embarazo

Llaguno MRI, Loján CMC, Lema BAJ, Castillo JEP, Flores AMJ

Idioma: Español
Referencias bibliográficas: 37
Paginas: 1245-1262
Archivo PDF: 256.54 Kb.


RESUMEN

El síndrome antifosfolipídico es un trastorno heterogéneo sistémico que se caracteriza por trombosis venosas y arteriales, complicaciones obstétricas y anticuerpos antifosfolipídicos persistentemente elevados. Esta revisión bibliográfica se realizó principalmente en Annual Reviews (https://www.annualreviews.org), Clinical Key (https://www.elsevier.com), US National Library of Medicine and National Institutes of Health en PMC (https://www.ncbi.nlm.nih.gov/pmc) y Scientific Electronic Library Open, SciELO (www.scielo.es). Se utilizó el descriptor síndrome antifosfolípido en inglés y español. Se describió el síndrome antifosfolípido primario, secundario y catastrófico. Dentro del primario se enfatizó en el tratamiento del obstétrico, con el propósito de prevenir las complicaciones trombóticas y obstétricas de la enfermedad y el empleo principalmente de la anticoagulación oral.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Vreede AP, Bockenstedt PL, Knight JS. Antiphospholipid syndrome: an update for clinicians and scientists. Curr Opin Rheumatol. 2017[citado 17/03/2020];29(5):458–466.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813838/pdf/nihms940493.pdf

  2. Radu A, Dudu SC, Ciobanu A, Peltecu G, Iancu G, Botezatu R, et al. Pregnancy Management in Women with Antiphospholidic Syndrome. Maedica (Buchar).2019 [citado 17/03/2020];14(2):148-160. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709396

  3. Tedesco F, Borghi MO, Gerosa M, Chighizola CB, Macor P, Lonati PA, et al. Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. Front Immunol.2018[citado 15/05/2019];9:1388. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018396/pdf/fimmu-09-01388.pdf

  4. Lopez Pedrera Ch, Barbarroja N, Patiño Trives AM, Collantes E, Aguirre A, Perez Sanchez C. New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics. Approaches Front Immunol. 2019 [citado 17/03/2020]; 10:764. Disponible en: https://www.frontiersin.org/articles/10.3389/fimmu.2019.00764/full

  5. Bertolaccini ML, Sanna G. Recent advances in understanding antiphospholipid syndrome. Version 1.2016[citado 17/03/2020];5.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224683/pdf/f1000research-5-10474.pdf

  6. Roggenbuck D, Borghi MO, Somma V, Büttner T, Schierack P, Hanack K, et al. Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Res Ther. 2016 [citado 17/03/ 2020]; 18(1):111. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875598/pdf/13075_2016_Article_1018.pdf

  7. Brusch A. The Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome. Antibodies (Basel). 2016[citado 17/03/2020]; 5(2):16. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698844/pdf/antibodies-05-00016.pdf

  8. Yelnik C, Porter TF, Branch DW, Laskin C, Merrill J, Guerra M, et al. Changes in Antiphospholipid Antibody Titers during Pregnancy: Data from the PROMISSE Study. Arthritis Rheumatol. 2016[citado 17/03/2020]; 68(8): 1964–1969. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380363/pdf/nihms854592.pdf

  9. McDonnell T, Wincup C, Buchholz I, Pericleous C, Giles I, Ripoll V, et al. The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. Blood Rev. 2020[citado 17/03/2020]; 39. Disponible en: https://www.sciencedirect.com/science/article/pii/S0268960X19300268

  10. Bertolaccini ML, Contento G, Lenner R, Sanna G, Blower PJ, Ma M, et al. Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. J Autoimmun. 2016[citado 17/04/2020];75: 30–38. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203312/pdf/emss-80165.pdf

  11. Yelnik C, Laskin C, Flint Porter T, Ware Branch D, Buyon J, Guerra M, et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL positive patients: validation of PROMISSE study results. Lupus Sci Med. 2016[citado 17/05/2020];3(1):e000131. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716418/

  12. Abrahams V, Chamley L, Salmon J. Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation. Arthritis Rheumatol. 2017[citado 17/02/2020]; 69(9): 1710–1721. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575987

  13. Wang D, Lv W, Zhang S, Zhang J. Advances in the Research on Anticardiolipin Antibody. J Immunol Res. 2019[citado 17/03/2020];2019. Disponible en: https://www.hindawi.com/journals/jir/2019/8380214/

  14. Sacharidou A, Shaul PW, Mineo C. New Insights in the Pathophysiology of Antiphospholipid Syndrome. Semin Thromb Hemost. 2018 [citado 17/06/2020];44(5):475–482. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333209/pdf/nihms-1005491.pdf

  15. Fleetwood T, Cantello R, Comi C. Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy. Front Neurol. 2018[citado 17/03/2020]; 9: 1001. Disponible en: https://www.frontiersin.org/articles/10.3389/fneur.2018.01001/full

  16. Madison J, Zuo Y, Knight J. Pediatric antiphospholipid syndrome. Eur J Rheumatol. 2020[citado 17/03/2020];7(Suppl 1): 3-12. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004270/

  17. Hwang JJ, Shin SH, Kim YJ, Oh YM, Lee SD, Kim YH, et al. Epidemiology of Antiphospholipid Syndrome in Korea: a Nationwide Population-based Study. J Korean Med Sci. 2020[citado 17 /03/2020]; 35(5):35. Disponible en: https://doi.org/10.3346/jkms.2020.35.e35

  18. Volkov I, Seguro L, Leon EP, Kovács L, Roggenbuck D, Schierack P, et al. Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome. Auto Immun Highlights. 2020[citado 17/02/2020]; 11(1):8. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229627/?report=reader

  19. Corban M, Duarte Garcia A, McBane R, Matteson EL, Lerman LO, Lerman A. Antiphospholipid Syndrome. Role of Vascular Endothelial Cells and Implications for Risk Stratification and Targeted Therapeutics. J Am Coll Cardiol. 2017 [citado 10/02/2020]; 69 (18): 2317-2330. Disponible en: https://www.sciencedirect.com/science/article/pii/S0735109717360485

  20. Rodríguez Pérez L, Castillo González D, Cabrera Payne Y, Tejeda González M. Síndrome antifosfolípido en mujeres con pérdidas recurrentes de embarazo: diagnóstico de laboratorio. Rev Cubana Hematol Inmunol Hemoter. 2015 [citado 10/03/2020];31(4).Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892015000400002&lng=es

  21. Velásquez M, Rojas M, Abrahams V, Escudero C, Cadavid Á. Mechanisms of Endothelial Dysfunction in Antiphospholipid Syndrome: Association With Clinical Manifestations. Front. Physiol.2018 [citado 17/04/2020]; 9:1840. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309735/pdf/fphys-09-01840.pdf

  22. Unlu O, Erkan D. Catastrophic Antiphospholipid Syndrome: Candidate Therapies for a Potentially Lethal Disease. Annu Rev Med. 2017[citado 17/04/2020];68:287–296. Disponible en: https://www.annualreviews.org/doi/pdf/10.1146/annurev-med-042915-102529

  23. Miyakis S, Lockshin MD, Atsumi T,Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 [citado 17/04/2020]; 4(2): 295–306. Disponible en: https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1538-7836.2006.01753.x

  24. Belhocine M, Coutte L, Silva NM, Morel N, Guettrot Imbert G, Paule R, et al. Intrauterine fetal deaths related to antiphospholipid syndrome: a descriptive study of 65 women. Arthritis Res Ther. 2018 [citado 17/04/ 2020]; 20:249. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235231/pdf/13075_2018_Article_1745.pdf

  25. Liu L, Sun D. Pregnancy outcomes in patients with primary antiphospholipid syndrome. A systematic review and meta-analysis. Medicine(Baltimore).2019[citado 17/04/2020]; 98:20(e15733). Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531250/

  26. Tektonidou M, Andreoli L, Limper M, Tincani A, Ward M. Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. RMD Open. 2019[citado 17/04/2020]; 5(1):e000924. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525610/pdf/rmdopen-2019-000924.pdf

  27. Andreoli L, Bertsias GK, Agmon Levin N, Brown S, Cervera R, Costedoat Chalumeau N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis.2017[citado 17/04/2020];76(3):476–485. Disponible en: http://dx.doi.org/10.1136/annrheumdis-2016-209770

  28. Cochery Nouvellon É, Mercier É, Bouvier S, Balducchi JP, Quéré I, Perez Martin A, et al. Obstetric antiphospholipid syndrome: early variations of angiogenic factors are associated with adverse outcomes. Haematologica. 2017[citado 17 abr 2020]; 102(5):835-842. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477602/pdf/1020835.pdf

  29. Limper M, Scirè CA, Talarico R, Amoura Z, Avcin T, Basile M, et al. Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD Open. [citado 17/04/2020] Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203101/pdf/rmdopen-2018-000785.pdf

  30. Chaturvedi S, McCrae K. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 2017[citado 17/02/2020]; 31(6): 406–417. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714279/pdf/nihms898473.pdf

  31. Grazia Lazzaroni M, Fredi M, Andreoli L, Chighizola CB, Del Ross T, Gerosa M, et al. Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. Front Immunol. 2019[citado 17/02/2020]; 10:1948. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702797/pdf/fimmu-10-01948.pdf

  32. Qushmaq NA, Al-Emadi SA. Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety. ISRN Rheumatol. 2014[citado 17 /02/2020];2014:348726.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040209/

  33. Ye SL, Gu XK, Tao LY, Cong JM, Wang YQ. Efficacy of Different Treatment Regimens for Antiphospholipid Syndrome related Recurrent Spontaneous Abortion. Chin Med J. 2017[citado 17/04/2020];130(12):1395 1399. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463467/

  34. Kazzaz N, McCune WJ, Knight J. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol.2016[citado 17/01/2020]; 28(3): 218–227. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958413/pdf/nihms-789797.pdf

  35. Costantine MM. Pravastatin to prevent obstetrical complications in women with antiphospholipid syndrome. J Clin Invest. 2016[citado 02/02/2020]; 126(8):2792–2794. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966319/pdf/JCI89137.pdf

  36. Garrett N, Pombo J, Umpierrez M, Clark JE, Simmons M, Girardi G. Pravastatin therapy during preeclampsia prevents long-term adverse health effects in mice. JCI Insight. 2018[citado 25/04/2019];3(8):120147. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931129/pdf/jciinsight-3-120147.pdf

  37. Vila Betancor JA, Solís Pérez Q, Medina Batista J. Actualización diagnóstico-terapéutica del síndrome antifosfolípido o de Hughes.CCM. 2018 [citado 30/05/2020];22(3).Disponible en: http://revcocmed.sld.cu/index.php/cocmed/article/view/2788




2020     |     www.medigraphic.com